Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 60

Sort by

Sort Order Select

Journal Articles

National Healthtree Survey on Pain and Opioid Use Patterns and Perceptions Among Patients with Multiple Myeloma

Karen Sweiss, Jay R. Hydren, Jorge Arturo Hurtado Martinez, Mason S. Barnes, Pritesh Patel, Douglas W Sborov, Jennifer M. Ahlstrom, Lisa Sharp, Craig C. Hofmeister

Blood (2024) 144 (Supplement 1): 283.

https://doi.org/10.1182/blood-2024-210314

Published: 2024

Journal Articles

Has ABO Mismatch Rate Decreased in AML and ALL Transplant Recipients over the Years, a Trend Analysis Using CIBMTR Data

Ahsan Wahab, Karen Sweiss, Noah Birch, Matias Sanchez

Blood (2024) 144 (Supplement 1): 2169.

https://doi.org/10.1182/blood-2024-209226

Published: 2024

Journal Articles

Feasibility and Target AUC Accuracy of Personalized High Dose Melphalan in Myeloma

Blood (2024) 144 (Supplement 1): 1993.

https://doi.org/10.1182/blood-2024-205614

Published: 2024

Journal Articles

Real-World Outcomes of Monoclonal Gammopathy of Renal Significance (MGRS) in the Era of Novel Therapies

Francesca Cottini, Ana Maria Avila Rodriguez, Karen Sweiss, Chukwuemeka Uzoka, Zhengjia Chen, Weiwei Ma, Elvira Umyarova, Anjali Satoskar, Pierre Rodriguez, Matias Sanchez

Blood (2024) 144 (Supplement 1): 3298.

https://doi.org/10.1182/blood-2024-198929

Published: 2024

Journal Articles

Haploidentical Peripheral Blood Stem Cell Transplantation in 20 Adult Patients with Sickle Cell Disease

Ekaterina Proskuriakova, Elisa Zucchetti, Karen Sweiss, Nadim Mahmud, Matthew Koshy, Damiano Rondelli, Santosh L. Saraf

Blood (2024) 144 (Supplement 1): 2101.

https://doi.org/10.1182/blood-2024-198407

Published: 2024

Journal Articles

ULTRA FRAIL-MM Clinical Trial: Go-Slow Approach Incorporating Isatuximab, Lenalidomide and Dexamethasone for Ultra-Frail Newly Diagnosed Myeloma

Ghulam Rehman Mohyuddin, Amandeep Godara, Brian McClune, Gliceida Galarza Fortuna, Karen Sweiss, Matias Sanchez, Hira Mian, Douglas W Sborov

Blood (2024) 144 (Supplement 1): 6916.

https://doi.org/10.1182/blood-2024-208861

Published: 2024

Journal Articles

Graft CD34+ Cell Dosing Adjustment Based on Body Surface Area As a Better Predictor of Hematopoietic Engraftment

Seungwon An, Youngmin Park, Celeste Mora, Chukwuemeka Uzoka, Matias Sanchez, Elisa Zucchetti, Karen Sweiss, Sally Campbell Lee, Damiano Rondelli, Nadim Mahmud

Blood (2024) 144 (Supplement 1): 7266.

https://doi.org/10.1182/blood-2024-210824

Published: 2024

Journal Articles

Association of Rh Mismatch with Primary Graft Failure and Overall Survival in Allogeneic Hematopoietic Stem Cell Recipients with Acute Leukemia, a CIBMTR Analysis

Ahsan Wahab, Karen Sweiss, Matias Sanchez

Blood (2024) 144 (Supplement 1): 3568.

https://doi.org/10.1182/blood-2024-209278

Published: 2024

Journal Articles

First Ever National Survey on Patient-Reported Efficacy and Safety of Cannabis in Patients with Multiple Myeloma

Karen Sweiss, Jay R. Hydren, Jorge Arturo Hurtado Martinez, Mason S. Barnes, Pritesh Patel, Douglas W. Sborov, Jennifer M. Ahlstrom, Lisa Sharp, Craig C. Hofmeister

Blood (2024) 144 (Supplement 1): 5144.

https://doi.org/10.1182/blood-2024-210437

Published: 2024

Journal Articles

RAMP up: Risk Adapted Post-Autologous Transplant Maintenance Therapy in MRD Positive Myeloma Patients

Karen Sweiss, Craig C. Hofmeister, Ghulam Rehman Mohyuddin, Amandeep Godara, Brian McClune, Damiano Rondelli, Danny Hadidi, David Chan, Matias Eugenio Sanchez, Min Hai, Mitch A. Phelps, Chukwuemeka Uzoka, Douglas Sborov

Blood (2023) 142 (Supplement 1): 4974.

https://doi.org/10.1182/blood-2023-191148

Published: 2023

Journal Articles

Free from Drug Therapy in Multiple Myeloma (FREEDMM): MRD-Based Cessation of Maintenance

Ana Maria Avila Rodriguez, Danny Hadidi, Craig C. Hofmeister, John Quigley, Maria Zappia, Maxim Frolov, Elizaveta Benevolenskaya, Matias Eugenio Sanchez, Shrihari Kadkol, Douglas Sborov, Damiano Rondelli, Chukwuemeka Uzoka, Karen Sweiss

Blood (2023) 142 (Supplement 1): 3395.

https://doi.org/10.1182/blood-2023-190011

Published: 2023

Journal Articles

Fludarabine Lymphodepletion Exposure Is Associated with Idecabtagene Vicleucel Toxicity in Relapsed and Refractory Multiple Myeloma Patients: Real-World Experience from the US Myeloma Immunotherapy Consortium

Blood (2023) 142 (Supplement 1): 4880.

https://doi.org/10.1182/blood-2023-187440

Published: 2023

Journal Articles

Addition of Myeloablative Doses of Total Marrow Irradiation (TMI) to Myeloablative Fludarabine/Busulfan Conditioning for Allogeneic HSCT in Patients with High-Risk AML, CML, or Myelodysplastic Syndrome: A Phase II Clinical Trial

Lucas Maahs, Matthew Koshy, Karen Sweiss, Kang-hyun Ahn, Zhengjia Chen, Chukwuemeka Uzoka, Carlos Galvez, Paul Rubinstein, John Quigley, Santosh L. Saraf, Ana Maria Avila Rodriguez, Bulent Aydogan, Nadim Mahmud, Damiano Rondelli

Blood (2023) 142 (Supplement 1): 4897.

https://doi.org/10.1182/blood-2023-179270

Published: 2023

Journal Articles

Effect of Predicted Fludarabine Lymphodepletion Exposure on Clinical Outcomes in Myeloma Patients Undergoing BCMA-CAR-T: An Exploratory Analysis from CARTITUDE-1

Blood (2022) 140 (Supplement 1): 4323–4324.

https://doi.org/10.1182/blood-2022-159501

Published: 2022

Journal Articles

Pre-Transplant Assessment of Adult Sickle Cell Patients Shows a High Prevalence of Psychosocial Frailties before Allogeneic Stem Cell Transplant

Karen Sweiss, Santosh L. Saraf, Alison Doane, Monika Mandava, Ryan Sun, Mahir Khan, Zacharie Paul Charles Hamilton, Jaleel G. Sweis, Victor R. Gordeuk, Damiano Rondelli, Lisa Sharp, Pritesh Patel

Blood (2022) 140 (Supplement 1): 5123–5124.

https://doi.org/10.1182/blood-2022-171103

Published: 2022

Journal Articles

Updated Analyses: Safety and Efficacy of Gemtuzumab Ozogamicin and Venetoclax in Patients with Relapsed or Refractory CD33+ Acute Myeloid Leukemia: A Phase Ib/II Study

Saad Arain, Ana Maria Avila, Sonia Christian, Pritesh Patel, Karen Sweiss, Brian Parkin, Santosh L. Saraf, Paul G. Rubinstein, Gregory S Calip, John G. Quigley

Blood (2022) 140 (Supplement 1): 11725–11726.

https://doi.org/10.1182/blood-2022-165615

Published: 2022

Journal Articles

Free from Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial): A Pilot Study of Minimal Residual Disease (MRD)-Driven Discontinuation of Maintenance

Karen Sweiss, Craig C Hofmeister, Maria Zappia, Maxim Frolov, Elizaveta Benevolenskaya, John G. Quigley, Shrihari Kadkol, Douglas W. Sborov, Damiano Rondelli, Pritesh Patel

Blood (2022) 140 (Supplement 1): 7304–7305.

https://doi.org/10.1182/blood-2022-170936

Published: 2022

Journal Articles

Predicted Fludarabine Exposure Is Independently Associated with CRS and ICANS after CD19 CAR T-Cell Therapy

Ivan J. Huang, Rosa Yeh, Karen Sweiss, Pritesh Patel, Alexandre Vinaud Hirayama, Erik L. Kimble, Krishna R. Juluri, Mazyar Shadman, Cameron J. Turtle, David G. Maloney, Jordan Gauthier

Blood (2022) 140 (Supplement 1): 12725–12727.

https://doi.org/10.1182/blood-2022-156751

Published: 2022

Journal Articles

Long-Term Adverse Events of Total Marrow Irradiation (TMI)-Based Conditioning Chemotherapy in Hematopoietic Stem Cell Transplant Recipients Treated on a Phase I/II Trial

Lucas Maahs, Pritesh Patel, Karen Sweiss, Chukwuemeka Uzoka, Nadim Mahmud, Ana Maria Avila, Matthew Koshy, Damiano Rondelli

Blood (2022) 140 (Supplement 1): 12913–12914.

https://doi.org/10.1182/blood-2022-163424

Published: 2022

Journal Articles

Safety and Efficacy of the Addition of the Protein Translation Inhibitor Omacetaxine to Induction with Cytarabine and Idarubicin in Newly Diagnosed AML

Samin Houshyar, Betul Gok Yavuz, Pritesh Patel, Nadim Mahmud, Karen Sweiss, Irum Khan, Santosh L. Saraf, Damiano Rondelli, Anwar Khan, John G. Quigley

Blood (2022) 140 (Supplement 1): 5957–5958.

https://doi.org/10.1182/blood-2022-170100

Published: 2022

NARROW

National Healthtree Survey on Pain and Opioid Use Patterns and Perceptions Among Patients with Multiple Myeloma

Has ABO Mismatch Rate Decreased in AML and ALL Transplant Recipients over the Years, a Trend Analysis Using CIBMTR Data

Feasibility and Target AUC Accuracy of Personalized High Dose Melphalan in Myeloma

Real-World Outcomes of Monoclonal Gammopathy of Renal Significance (MGRS) in the Era of Novel Therapies

Haploidentical Peripheral Blood Stem Cell Transplantation in 20 Adult Patients with Sickle Cell Disease

ULTRA FRAIL-MM Clinical Trial: Go-Slow Approach Incorporating Isatuximab, Lenalidomide and Dexamethasone for Ultra-Frail Newly Diagnosed Myeloma

Graft CD34+ Cell Dosing Adjustment Based on Body Surface Area As a Better Predictor of Hematopoietic Engraftment

Association of Rh Mismatch with Primary Graft Failure and Overall Survival in Allogeneic Hematopoietic Stem Cell Recipients with Acute Leukemia, a CIBMTR Analysis

First Ever National Survey on Patient-Reported Efficacy and Safety of Cannabis in Patients with Multiple Myeloma

RAMP up: Risk Adapted Post-Autologous Transplant Maintenance Therapy in MRD Positive Myeloma Patients

Free from Drug Therapy in Multiple Myeloma (FREEDMM): MRD-Based Cessation of Maintenance

Fludarabine Lymphodepletion Exposure Is Associated with Idecabtagene Vicleucel Toxicity in Relapsed and Refractory Multiple Myeloma Patients: Real-World Experience from the US Myeloma Immunotherapy Consortium

Addition of Myeloablative Doses of Total Marrow Irradiation (TMI) to Myeloablative Fludarabine/Busulfan Conditioning for Allogeneic HSCT in Patients with High-Risk AML, CML, or Myelodysplastic Syndrome: A Phase II Clinical Trial

Effect of Predicted Fludarabine Lymphodepletion Exposure on Clinical Outcomes in Myeloma Patients Undergoing BCMA-CAR-T: An Exploratory Analysis from CARTITUDE-1

Pre-Transplant Assessment of Adult Sickle Cell Patients Shows a High Prevalence of Psychosocial Frailties before Allogeneic Stem Cell Transplant

Updated Analyses: Safety and Efficacy of Gemtuzumab Ozogamicin and Venetoclax in Patients with Relapsed or Refractory CD33+ Acute Myeloid Leukemia: A Phase Ib/II Study

Free from Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial): A Pilot Study of Minimal Residual Disease (MRD)-Driven Discontinuation of Maintenance

Predicted Fludarabine Exposure Is Independently Associated with CRS and ICANS after CD19 CAR T-Cell Therapy

Long-Term Adverse Events of Total Marrow Irradiation (TMI)-Based Conditioning Chemotherapy in Hematopoietic Stem Cell Transplant Recipients Treated on a Phase I/II Trial

Safety and Efficacy of the Addition of the Protein Translation Inhibitor Omacetaxine to Induction with Cytarabine and Idarubicin in Newly Diagnosed AML

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only